Scotiabank analyst George Farmer maintained a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $42.97.
Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Tempest Therapeutics, and SAGE Therapeutics. According to TipRanks, Farmer has an average return of 14.5% and a 51.22% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $86.00 average price target, a 100.14% upside from current levels. In a report released today, BMO Capital also reiterated a Buy rating on the stock with a $90.00 price target.
The company has a one-year high of $77.32 and a one-year low of $42.08. Currently, Legend Biotech has an average volume of 1.02M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Legend Biotech (LEGN) Company Description:
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm’s lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
